As an IgG1-like bispecific antibody, it binds MET on target cells and its Fc engages Fcγ receptor–bearing effector cells (e.g., NK cells) to induce ADCC (and potentially CDC), killing MET-expressing cells; signaling blockade itself is non-cytotoxic.